REVISION OF THE MONOGRAPH ON
MEDROXYPROGESTERONE INJECTION

(June 2016)

DRAFT FOR COMMENT

Should you have any comments on the attached text, please send these to Dr Herbert Schmidt, Medicines Quality Assurance, Technologies, Standards and Norms, World Health Organization, 1211 Geneva 27, Switzerland; email: schmidt@who.int; fax: (+41 22) 791 4730 by 12 August 2016.

In order to speed up the process for receiving draft monographs and for sending comments, please let us have your email address (to bonnyw@who.int) and we will add it to our electronic mailing list. Please specify if you wish to receive monographs.

© World Health Organization 2016

All rights reserved.

This draft is intended for a restricted audience only, i.e. the individuals and organizations having received this draft. The draft may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means outside these individuals and organizations (including the organizations’ concerned staff and member organizations) without the permission of the World Health Organization. The draft should not be displayed on any website.

Please send any request for permission to:

Dr Sabine Kopp, Group Lead, Medicines Quality Assurance, Technologies Standards and Norms, Department of Essential Medicines and Health Products, World Health Organization, CH-1211 Geneva 27, Switzerland.
Fax: (41-22) 791 4730; email: kopp@who.int.

The designations employed and the presentation of the material in this draft do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this draft. However, the printed material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This draft does not necessarily represent the decisions or the stated policy of the World Health Organization.
**SCHEDULE FOR THE ADOPTION PROCESS OF DOCUMENT QAS/16.670**

**REVISION OF THE MONOGRAPH ON**

**MEDROXYPROGESTERONE INJECTION**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2016</td>
<td>First draft prepared by the Secretariat</td>
</tr>
<tr>
<td>9–11 May 2016</td>
<td>Discussion at Consultation on quality control laboratory tools and specifications for medicines</td>
</tr>
<tr>
<td>June–August 2016</td>
<td>First draft sent out for public consultation</td>
</tr>
<tr>
<td>October 2016</td>
<td>Presentation to WHO Expert Committee on Specifications for Pharmaceutical Preparations for adoption</td>
</tr>
<tr>
<td></td>
<td>Further follow-up action as required</td>
</tr>
</tbody>
</table>
REVISION OF THE MONOGRAPH ON
MEDROXYPROGESTERONE INJECTION

[Note from the Secretariat. Following information received from our custodian centre for International Chemical Reference Substances (ICRS), the European Directorate for the Quality of Medicines & HealthCare, it is proposed to revise the monograph on Medroxyprogesterone injection.

Changes from the current monograph are indicated in the text by insert or delete.]

Medroxyprogesterone injection (Medroxyprogesteroni injectio)

Category. Contraceptive.

Storage. Medroxyprogesterone injection should be protected from light. On standing solid matter may separate; it should be resuspended before use.

Additional information. Strength in the current WHO Model List of Essential Medicines: 150 mg/mL in 1 mL vial.

Requirements

Complies with the monograph for Parenteral preparations.

Definition. Medroxyprogesterone injection is a sterile aqueous suspension of Medroxyprogesterone acetate. It contains not less than 90.0% and not more than 110.0% of the amount of Medroxyprogesterone acetate (C_{24}H_{34}O_{4}) stated on the label.

Identity tests

- Either test A alone or tests B and C or tests C and D may be applied.

A. Centrifuge a volume of the injection to be examined containing 50 mg of Medroxyprogesterone acetate. Decant the supernatant liquid and discard. Dry the residue at 105 °C for 3 hours and carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from medroxyprogesterone acetate RS or with the reference spectrum of medroxyprogesterone acetate.

B. Carry out test B.1 or, where UV detection is not available, test B.2.

B.1 Carry out the test as described under 1.14.1 Thin-layer chromatography using silica R5 as the coating substance and a mixture of 10 volumes of
dichloromethane R and 1 volume of ethyl acetate R as the mobile phase. Apply separately to the plate 10 μL of each of the following three solutions in dichloromethane R. For solution (A) measure a volume of injection to be examined containing about 25 mg of Medroxyprogesterone acetate, add 15 mL of dichloromethane R, shake vigorously for 20 minutes, allow to stand for 30 minutes, add 2.5 g sodium sulphate anhydrous R, shake for 5 minutes and allow to stand for another 10 minutes. For solution (B) use 2.5 mg of medroxyprogesterone acetate RS per mL. For solution (C) use 5 mg of medroxyprogesterone acetate RS and 0.2 mg of medroxyprogesterone acetate impurity F RS per mL. After removing the plate from the chromatographic chamber heat it at 120 °C for 30 minutes, spray with 4-toluenesulphonic acid/ethanol TS and heat further at 120 °C for 10 minutes. Allow the plate to cool and examine the chromatogram in ultraviolet light (365 nm). The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

B.2 Carry out the test as described under 1.14.1 Thin-layer chromatography using the conditions described under test B.1, but spray the plate with a mixture of equal volumes of sulfuric acid R and ethanol (~750 g/L) TS and heat further at 120 °C for 10 minutes. Allow the plate to cool and examine the chromatogram in daylight. The test is not valid unless the chromatogram obtained with solution (C) shows two clearly separated spots.

The principal spot obtained with solution (A) corresponds in position, appearance and intensity to that obtained with solution (B).

C. Centrifuge a volume of injection to be examined containing 30 mg of Medroxyprogesterone acetate. Decant the supernatant liquid, dissolve the residue in 5 mL of sulfuric acid R and introduce 5 mL of ethanol (~750 g/L) TS to form an upper layer; a bluish violet ring is formed at the interface of the two layers.

D. See the test described below under “Assay”. The retention time of the principal peak in the chromatogram obtained with solution (1) is similar to that in the chromatogram obtained with solution (2).

pH. pH of the injection, 3.0–7.0.

Impurity F (4,5-Dihydromedroxyprogesterone acetate). Carry out the test as described under 1.14.1 Thin-layer chromatography using silica gel R5 as the coating substance and a mixture of 10 volumes of tetrahydrofuran R, 45 volumes of tert-butyl methyl ether R and 45 volumes of hexane R as the mobile phase.

Apply separately to the plate 10 μL of each of the following two solutions in dichloromethane R. For solution (A) accurately measure a volume of injection to be
examined containing 300 mg of Medroxyprogesterone acetate, add 15 mL of
dichloromethane R, shake vigorously for 20 minutes, allow to stand for 30 minutes, add 10 g
sodium sulphate anhydrous R, shake for 5 minutes and allow to stand for another 10 minutes.
For solution (B) dilute 0.5 volume of solution (1) to 100 volumes. For solution (BC) use 20
mg of medroxyprogesterone acetate RS and 0.1 mg of medroxyprogesterone acetate impurity
F RS per mL.

Develop the plate for a distance of about 10 cm. Allow it to dry in air and carry out a second
development in the same direction using a freshly prepared mobile phase. After removing the
plate from the chromatographic chamber heat it at 100 °C to 105 °C for 30 minutes and spray
with 4-toluenesulfonic acid/ethanol TS. Heat again at 120 °C for 10 minutes, allow to cool
and examine the chromatogram in ultraviolet light (365 nm).

In the chromatogram obtained with solution (BC) impurity F has a R<sub>f</sub> value of about 0.66 and
medroxyprogesterone acetate a R<sub>f</sub> value of about 0.56. The test is not valid unless the
chromatogram obtained with solution (BC) shows two clearly separated spots. In the
chromatogram obtained with solution (A) any spot due to impurity F is not more intense than
the corresponding spot in the chromatogram obtained with solution (B) (0.5%).

**Related substances**

Prepare fresh solutions and perform the tests without delay.

Carry out the test as described under 1.14.4 High-performance liquid chromatography using
the conditions given under “Assay”.

Prepare the following solutions with the mobile phase. For solution (1) dilute a suitable
volume of the injection to be examined to obtain a concentration of 0.4 mg of
Medroxyprogesterone acetate per mL. For solution (2) dilute a suitable volume of solution (1)
to obtain a concentration of 4 μg of Medroxyprogesterone acetate per mL. For solution (2)
dilute 1.0 mL of solution (1) to 100.0 mL. For solution (3) use 0.05 mg of
medroxyprogesterone acetate RS and 0.05 mg of medroxyprogesterone acetate impurity G
RS per mL. For solution (3) dissolve 4 mg of medroxyprogesterone acetate for system
suitability RS (containing medroxyprogesterone acetate and the impurities A, B, C, D, E, G
and I) and dilute to 2.0 mL. For solution (4) use 3.65 μg of methyl hydroxybenzoate R and
0.4 μg of propyl hydroxybenzoate R per mL.

Inject separately 20 μL of solution (1), (2), (3) and (4). Record the chromatogram for about
twice the retention time of medroxyprogesterone acetate in solution (2).

Use the chromatogram supplied with medroxyprogesterone acetate for system suitability RS
and the chromatogram obtained with solution (4) to identify the peaks due to impurities A, B,
C, D, E, G and I. The impurities are eluted at the following relative retention with reference
to the peak of medroxyprogesterone acetate (retention time about 27 minutes): impurity A
about 0.3; impurity I about 0.5; impurity H about 0.65; impurity B about 0.7; impurity C
about 0.8; impurity G about 0.85; impurity D about 0.9; impurity E about 0.95.
In the chromatogram obtained with solution (3) impurity G is eluted at a relative retention of about 0.86 with reference to medroxyprogesterone acetate (retention time about 15 minutes). The test is not valid unless the resolution factor between the peaks due to medroxyprogesterone acetate and due to impurity G is at least 3.3.

In the chromatogram obtained with solution (1):

- the area of any peak, other than the principal peak, is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (1.0%);
- the sum of the areas of all peaks, other than the principal peak, is not greater than 1.5 times the area of the principal peak in the chromatogram obtained with solution (2) (1.5%). Disregard any peak due to hydroxybenzoate derivatives in the chromatogram obtained with solution (4). Disregard any peak with an area less than 0.05 times the area of the principal peak obtained with solution (2) (0.05%).

**Assay**

Carry out the test as described under **1.14.4 High-performance liquid chromatography** using a stainless steel column (25 cm × 4.6 mm) packed with particles of silica gel, the surface of which has been modified with chemically-bonded octadecylsilyl groups (5 µm).

As the mobile phase use a solution prepared as follows: mix 100 volumes of tetrahydrofuran R, 350 volumes of acetonitrile R and 500 volumes of water R.

Prepare the following solutions in the mobile phase. For solution (1) dilute a suitable volume of the injection to be examined to obtain a concentration of 40 µg of Medroxyprogesterone acetate per mL. For solution (2) dissolve 10 mg of medroxyprogesterone acetate RS in 50 mL. Dilute 5 mL of this solution to 25 mL. For solution (3) use 0.5 mg of medroxyprogesterone acetate RS and 0.5 mg medroxyprogesterone acetate impurity G RS per mL.

Operate with a flow rate of 0.9 mL per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 241 nm.

Inject 20 µL of solutions (3). Impurity G is eluted at a relative retention of about 0.86 with reference to medroxyprogesterone acetate (retention time about 15 minutes). The test is not valid unless the resolution factor between the peaks due to medroxyprogesterone acetate and due to impurity G is at least 3.3.

Inject separately 20 µL of solution (1) and (2).

Measure the areas of the peak responses obtained in the chromatograms from solutions (1) and (2) and calculate the percentage content of medroxyprogesterone acetate (C_{24}H_{34}O_{4}), using the declared content of C_{24}H_{34}O_{4} in medroxyprogesterone acetate RS.